Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 6 studies | 21% ± 2% | |
glutamatergic neuron | 6 studies | 35% ± 18% | |
neuron | 4 studies | 27% ± 3% | |
epithelial cell | 4 studies | 29% ± 8% | |
GABAergic neuron | 4 studies | 33% ± 11% | |
basal cell | 3 studies | 22% ± 3% | |
macrophage | 3 studies | 20% ± 2% | |
oligodendrocyte | 3 studies | 22% ± 2% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 31% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5413.72 | 1445 / 1445 | 100% | 48.09 | 183 / 183 |
breast | 100% | 4746.35 | 459 / 459 | 100% | 52.11 | 1117 / 1118 |
prostate | 100% | 4626.95 | 245 / 245 | 100% | 32.18 | 501 / 502 |
lung | 100% | 4047.65 | 576 / 578 | 100% | 36.32 | 1154 / 1155 |
brain | 100% | 4356.27 | 2629 / 2642 | 100% | 46.00 | 705 / 705 |
uterus | 100% | 7249.89 | 170 / 170 | 99% | 42.65 | 456 / 459 |
bladder | 100% | 5581.86 | 21 / 21 | 99% | 29.88 | 500 / 504 |
thymus | 100% | 3368.64 | 652 / 653 | 99% | 31.41 | 600 / 605 |
ovary | 100% | 4145.33 | 180 / 180 | 99% | 23.40 | 424 / 430 |
kidney | 100% | 2350.69 | 89 / 89 | 98% | 28.43 | 884 / 901 |
intestine | 100% | 4984.55 | 966 / 966 | 98% | 23.57 | 517 / 527 |
stomach | 100% | 2939.29 | 359 / 359 | 98% | 26.36 | 280 / 286 |
skin | 100% | 5987.74 | 1809 / 1809 | 97% | 53.59 | 459 / 472 |
adrenal gland | 100% | 3247.28 | 258 / 258 | 97% | 30.74 | 222 / 230 |
liver | 100% | 2268.68 | 226 / 226 | 93% | 17.02 | 378 / 406 |
pancreas | 92% | 1430.52 | 301 / 328 | 98% | 28.34 | 175 / 178 |
adipose | 100% | 4520.29 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6950.80 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 20.67 | 29 / 29 |
muscle | 100% | 9350.64 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3476.63 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 44.58 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.66 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 98% | 37.02 | 78 / 80 |
heart | 97% | 3686.52 | 831 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 50% | 1351.13 | 467 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0060743 | Biological process | epithelial cell maturation involved in prostate gland development |
GO_0006915 | Biological process | apoptotic process |
GO_0060442 | Biological process | branching involved in prostate gland morphogenesis |
GO_0016567 | Biological process | protein ubiquitination |
GO_0051438 | Biological process | regulation of ubiquitin-protein transferase activity |
GO_2000001 | Biological process | regulation of DNA damage checkpoint |
GO_1902041 | Biological process | regulation of extrinsic apoptotic signaling pathway via death domain receptors |
GO_0140627 | Biological process | ubiquitin-dependent protein catabolic process via the C-end degron rule pathway |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0031462 | Cellular component | Cul2-RING ubiquitin ligase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0005123 | Molecular function | death receptor binding |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | FEM1B |
Protein name | Protein fem-1 homolog B (FEM1b) (FEM1-beta) (Fem-1-like death receptor-binding protein alpha) (Fem-1-like in apoptotic pathway protein alpha) (F1A-alpha) Fem-1 homolog B |
Synonyms | F1AA KIAA0396 |
Description | FUNCTION: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation . The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms . The CRL2(FEM1B) complex specifically recognizes proteins ending with -Gly-Leu-Asp-Arg, such as CDK5R1, leading to their ubiquitination and degradation . Also acts as a regulator of the reductive stress response by mediating ubiquitination of reduced FNIP1: in response to reductive stress, the CRL2(FEM1B) complex specifically recognizes a conserved Cys degron in FNIP1 when this degron is reduced, leading to FNIP1 degradation and subsequent activation of mitochondria to recalibrate reactive oxygen species (ROS) (By similarity). Mechanistically, recognizes and binds reduced FNIP1 through two interface zinc ions, which act as a molecular glue that recruit reduced FNIP1 to FEM1B (By similarity). Promotes ubiquitination of GLI1, suppressing GLI1 transcriptional activator activity . Promotes ubiquitination and degradation of ANKRD37 (By similarity). Promotes ubiquitination and degradation of SLBP . Involved in apoptosis by acting as a death receptor-associated protein that mediates apoptosis . Also involved in glucose homeostasis in pancreatic islet (By similarity). May also act as an adapter/mediator in replication stress-induced signaling that leads to the activation of CHEK1 . . |
Accessions | ENST00000306917.5 H3BT12 H3BTV3 ENST00000566008.1 Q9UK73 ENST00000566739.1 |